In January 2026, Sweden began offering low-dose aspirin as a standard treatment for bowel cancer patients with specific genetic mutations, a policy shift driven by a decade-long trial showing the drug halved colorectal cancer risk in high-risk groups.
The change follows results from a landmark study led by Professor John Burn at Newcastle University, which tracked 861 patients with Lynch Syndrome for ten years. Those who took a daily 600mg dose of aspirin for at least two years had a 50% lower incidence of colorectal cancer compared to those on placebo.
Lynch Syndrome carriers face an 80% lifetime risk of developing bowel cancer, making them a critical population for testing preventive strategies. Burn’s 2020 findings provided the first strong evidence from a randomized controlled trial that aspirin could interrupt cancer development in this group.
Earlier hints of aspirin’s anti-cancer potential emerged in 2010 when Professor Peter Rothwell re-analyzed cardiovascular trial data and observed reduced cancer incidence and spread among aspirin users. Still, proving preventive effects in the general population remains impractical due to cancer’s long latency period.
As Anna Martling, professor of surgery at the Karolinska Institute, noted, conducting a decades-long placebo-controlled trial for cancer prevention in healthy people is “almost impossible, actually” as of the time and cost involved.
This has steered research toward genetically predisposed or previously affected populations, where outcomes can be measured within a feasible timeframe. The UK has responded by updating guidelines to recommend aspirin for high-risk individuals as young as 20.
Scientists now understand aspirin works through two primary mechanisms: it inhibits the Cox-2 enzyme, reducing hormones that fuel uncontrolled cell growth, and it thins the blood by blocking thromboxane A2, which may prevent cancer cells from evading immune detection by hiding in clots.
Despite the promise, experts caution against broad use. Regular aspirin carries risks of internal bleeding, stomach ulcers, and brain hemorrhages, particularly with long-term use.
Anna Martling warns that giving aspirin to healthy populations introduces harm where none existed before, arguing it is fundamentally different from treating those already at high risk.
While some researchers advocate for widespread low-dose aspirin use in people over 50 to lower national mortality, Martling and others insist the drug should be reserved for high-risk groups under medical supervision.
Ongoing trials involving 11,000 participants across the UK, Ireland, and India are investigating whether aspirin protects against breast, prostate, and esophageal cancers, with results expected in 2027.
Who should consider taking aspirin for cancer prevention?
Current evidence supports aspirin use only for individuals with Lynch Syndrome or other high-risk genetic profiles, and only under strict medical supervision due to bleeding risks.
Why isn’t aspirin recommended for everyone despite its benefits?
Because aspirin can cause serious side effects like internal bleeding and ulcers, experts argue its use must be limited to those whose cancer risk outweighs these dangers, such as genetically susceptible populations.
